How should I evaluate and manage an adult with overactive bladder, including diagnostic work‑up, first‑line behavioral therapy, medication options, and treatments for refractory cases?

Overactive Bladder: Evaluation and Management

Diagnosis

Overactive bladder is diagnosed clinically when a patient reports bothersome urgency (the hallmark symptom), with or without urgency incontinence, usually accompanied by frequency and nocturia, after excluding urinary tract infection and other obvious pathology. 1

Essential Initial Workup

• History and physical examination must document urgency as the primary symptom, distinguish storage symptoms (frequency, urgency, nocturia) from voiding symptoms (weak stream, hesitancy, incomplete emptying), and assess fluid intake, caffeine/alcohol consumption, and medications 1
• Urinalysis is mandatory to exclude urinary tract infection before initiating any treatment 1, 2
• Post-void residual (PVR) measurement should be performed in patients with emptying symptoms, history of urinary retention, prior pelvic surgery, or long-standing diabetes 2
  • Critical pitfall: Failure to measure PVR can lead to misdiagnosing overflow incontinence as OAB, resulting in antimuscarinic treatment that worsens urinary retention 2
  • Antimuscarinics should be used with extreme caution when PVR ≥250-300 mL 2

Key Differential Diagnoses to Exclude

• Urinary tract infection: Requires urinalysis and culture if indicated 1
• Nocturnal polyuria: Distinguished by normal or large-volume nocturnal voids (versus small-volume voids in OAB) 1
• Interstitial cystitis/bladder pain syndrome: Characterized by bladder or pelvic pain and dyspareunia, which are absent in OAB 1
• Polydipsia-induced frequency: Identified using frequency-volume charts showing physiologic polyuria 1
• Hematuria not associated with infection: Mandates urologic evaluation 2

Useful Diagnostic Tools

• Bladder diary/frequency-volume chart reliably measures voiding frequency and incontinence episodes 1, 3
• Symptom questionnaires help quantify severity and track treatment response 1

---

First-Line Treatment: Behavioral Therapies

All patients with OAB must receive behavioral therapies as first-line treatment, which can be combined with pharmacologic management for optimal results. 1, 2

Core Behavioral Interventions

• Bladder training with scheduled voiding and urgency-suppression techniques has the strongest evidence among behavioral interventions 1, 2
• Fluid management: Optimize total daily volume, reduce evening intake, and limit caffeine and alcohol 1, 2
• Dietary modifications: Avoid acidic foods and artificial sweeteners 2
• Pelvic floor muscle exercises (with or without biofeedback) improve continence control 2
• Weight reduction in overweight patients, as 8% weight loss reduces urgency incontinence episodes by 42% versus 26% in controls 2

Important Comorbidities to Address

• Constipation, obesity, diabetes, and pelvic organ prolapse can exacerbate OAB and should be optimized concurrently 2
• Genitourinary syndrome of menopause should be treated in postmenopausal women 2

---

Second-Line Treatment: Pharmacologic Management

Clinicians should offer either antimuscarinic medications or beta-3 agonists (mirabegron) to improve urgency, frequency, and urgency incontinence after inadequate response to behavioral therapy. 1, 2

Medication Options

• Antimuscarinic agents: Oxybutynin, tolterodine, solifenacin, darifenacin, trospium 1, 2
• Beta-3 agonist: Mirabegron (25-50 mg daily) 1
• Both classes have equivalent efficacy and are appropriate first-line pharmacologic options 1, 2

Combination Therapy for Refractory Cases

For patients refractory to monotherapy with either antimuscarinics or beta-3 agonists, combination therapy with an antimuscarinic and beta-3 agonist should be considered. 1

Treatment Optimization

• Combine medication with ongoing behavioral interventions for superior symptom improvement 2
• Reassess at 2-4 weeks for efficacy and adverse events 1, 2
• Consider dose modification or alternate medication if initial treatment is effective but adverse events are intolerable 1
• Actively manage adverse events such as dry mouth and constipation 1

Safety Considerations

• Antimuscarinics can precipitate urinary retention when PVR ≥250-300 mL 2
• Use caution in elderly patients due to risk of cognitive impairment 2

---

Third-Line Treatment: Advanced Therapies

Patients who fail combined behavioral and pharmacologic management after an adequate trial (3-6 months) should be referred to urology for consideration of third-line therapies. 1, 2

Third-Line Options

• Intradetrusor onabotulinumtoxinA injection (patients must be willing to perform clean intermittent self-catheterization if needed) 1
• Sacral neuromodulation (SNS) 1
• Peripheral tibial nerve stimulation (PTNS) (requires frequent office visits) 1

Extremely Rare Last-Resort Options

• Augmentation cystoplasty or urinary diversion should only be considered in extremely rare cases after all other treatments have failed 1

---

Referral Criteria to Urology

Refer to urology when:

• Failure of adequate trial (3-6 months) of combined behavioral and pharmacologic therapy 2
• Hematuria not attributable to infection 2
• Recurrent urinary tract infections (≥3 per year) 2
• Neurological signs suggestive of neurogenic bladder 2
• Elevated PVR >250-300 mL suggesting significant outlet obstruction 2
• Patient desires consideration of third-line therapies 2

---

Critical Pitfalls to Avoid

• Do not initiate antimuscarinics without measuring PVR in patients with emptying symptoms, prior retention, or diabetes 2
• Do not refer prematurely before completing a full course of behavioral and pharmacologic therapy 2
• Do not overlook comorbid conditions (constipation, obesity, diabetes, menopause) that exacerbate OAB 2
• Do not assume all urgency is OAB: Rule out infection, interstitial cystitis, bladder stones, and bladder cancer 2
• Recognize that OAB is a quality-of-life condition that generally does not affect survival, so treatment decisions should carefully weigh benefits against risks and reversibility of adverse events 1